Market Intelligence, Clinical Progress, and High-Purity Reagents for Epitranscriptomics and Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIAA1429/VIRMA drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIAA1429 Recombinant Domain Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View KIAA1429 Products |
| Gene Delivery | KIAA1429 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View KIAA1429 Products |
| Benchmark Ab | Anti-KIAA1429 Antibody Recombinant positive control. |
View KIAA1429 Products |
| Validator | KIAA1429 siRNA Set For knockdown verification. |
View KIAA1429 Products |
| Related Target A | METTL3 Core catalytic subunit of the m6A methyltransferase complex. |
View METTL3 Products |
| Related Target B | WTAP Regulatory subunit interacting directly with KIAA1429 to guide m6A deposition. |
View WTAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Reconstitution & Stability | HEK293-expressed KIAA1429 fragment domains with verified sequence and theoretical MW confirmation. |
| Protein-Protein Interaction (PPI) Screen | High-purity KIAA1429 and WTAP/METTL3 partner proteins strictly controlled for batch-to-batch consistency. |
| Lack of Controls | Sequence-verified clinical-grade benchmark antibodies included. |
| False Positives in Knockdown | Highly specific siRNA sets included for orthogonal target validation. |
Live KIAA1429/VIRMA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for epitranscriptomic therapeutics is intensifying, with major players shifting focus from direct catalytic inhibitors to protein-protein interaction (PPI) disruptors and targeted protein degraders (PROTACs). As first-generation METTL3 inhibitors progress through early clinical trials, the next wave of R&D is targeting KIAA1429 (VIRMA) to disrupt the scaffold assembly of the m6A writer complex in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI) | Epigenetic Biotech Startups | Hepatocellular Carcinoma, Breast Cancer | Direct Binding Assays (Need high-purity KIAA1429 interaction domains) |
| Targeted Protein Degradation (PROTAC) | TPD Specialists | Glioblastoma, Solid Tumors | Ubiquitination & Ternary Complex Assays (Need sequence-verified recombinant proteins) |
| RNA Therapeutics | Antisense/siRNA Developers | Refractory Cancers | In vitro target knockdown validation (Need validated siRNA/Lentivirus controls) |